| |
 | |  |
|
| |
|
New Paper in Science Features Infinity's IPI-926 Hedgehog Pathway Inhibitor as a Promising New Approach in Chemo-Resistant Pancreatic Cancer
(29/May/2009)
|
|
CAMBRIDGE, Mass., May 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced the recent publication of a new scientific paper further supporting Hedgehog signaling pathway inhibition as a promising new approach to treat cancer. The data featured in the paper show that IPI-926, when administered in combination with gemcitabine in a preclinical mouse model of treatment-resistant pancreatic cancer, increased tumor cell death, resulting in a reduction of
|
|
|
|
Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial Of CPI-613 For Treatment Of Pancreatic Cancer
(28/May/2009)
|
|
Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced today that it has begun a phase I/II clinical trial of CPI-613, the initial candidate to emerge from the company's Altered Energy Metabolism Directed technology platform. (Source: Pharmaceutical Online News)
|
|
|
|
Pancreatic Cancer Research Receives $18 Million Boost
(28/May/2009)
|
|
The Translational Genomics Research Institute (TGen) and the University of Pennsylvania (Penn) will receive $18 million to research pancreatic cancer, Stand Up to Cancer (SU2C) has announced. Dr. Daniel Von Hoff, TGen's Physician-In-Chief, and Dr. Craig B. (Source: Health News from Medical News Today)
|
|
|
|
How Viral Infection Can Protect From Type 1 Diabetes
(28/May/2009)
|
|
Type 1 diabetes is caused by immune system–mediated destruction of insulin-producing beta-cells in the pancreas. It is known that infection with a virus can induce an immune response that damages beta-cells or a response that protects an individual from type 1 diabetes. (Source: ScienceDaily Headlines)
|
|
|
|
$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research
(27/May/2009)
|
|
(The Translational Genomics Research Institute) Dr. Daniel Von Hoff, TGen's Physician-In-Chief, and Dr. Craig B. Thompson, Director of the Abramson Cancer Center at Penn, are co-leaders of SU2C pancreatic cancer "Dream Team.'' (Source: EurekAlert! - Medicine and Health)
|
|
|
|
Queensland Government Funds Univeristy Of Queensland Cancer Fight
(25/May/2009)
|
|
University of Queensland (UQ) researchers will use a $5 million grant from the Queensland State Government to unlock the genetic causes of pancreatic and ovarian cancer. The funding was announced overnight by Queensland Trade Minister Stephen Robertson at the world's largest biotechnology conference, Bio, in Atlanta, USA. (Source: Health News from Medical News Today)
|
|
|
|
Low blood supply limits cancer drug
(23/May/2009)
|
|
Scientists have discovered a new mechanism that may explain why pancreatic cancer patients are often resistant to a common chemotherapy treatment (Source: Pharmacy Europe)
|
|
|
|
Wash. Has 1st Death Under New Suicide Law
(22/May/2009)
|
|
A 66-year-old woman who had stage 4 pancreatic cancer is the first person to die under Washington state's new assisted suicide law. (Source: Health News: CBSNews.com)
|
|
|
|
Study Shows Pancreatic Cancer Drug May Fail
(22/May/2009)
|
|
A poor network of blood vessels may explain why some people with pancreatic cancer are often resistant to a common chemotherapy treatment, international researchers said on Thursday. (Source: Health Behavior News Digest)
|
|
|
|
Wash. Woman Dies Under New Assisted Suicide Law
(22/May/2009)
|
|
A 66-year-old woman who had pancreatic cancer has become the first person to die under Washington state's new assisted suicide law. (Source: FOXNews.com)
|
|
|
| |
| | |
|